EICHORCondition: Metabolic Dysfunction-associated Steatotic Liver Disease · Chronic Hepatitis b · Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is a Phase Ib, multicenter randomized, double-blind, dose-escalation, placebo-controlled trial designed to evaluate the safety, tolerability, PK, and PD profiles of multiple-dose ACT500 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated with chronic hepatitis B (CHB). The trial plans to enroll 24 participants with MASLD complicated with CHB across three dose cohorts initially, each consisting of 8 participants who will receive oral ACT500 tablets once daily.
This description comes directly from the study's public registry record.
Jidong Jia, Ph.D · 13501378269 · jia_jd@ccmu.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing Friendship Hospital, Capital Medical University | Beijing, China | — |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, China | — |
| The First Affiliated Hospital of Xinjiang Medical University | Ürümqi, China | — |
| Xiamen Hospital of Traditional Chinese Medicine | Xiamen, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07589400